Kymathera raises $80 million Series B financing
Kymathera announced an $80 million Series B financing led by Alta Partners to advance K-1728, a next-generation selective Pi3kα inhibitor for cancer and vascular malformations.
Oct. 6 — Kymathera announced $80 million in Series B financing to advance K-1728, a next-generation pan-mutant selective PI3Kα inhibitor, for cancer and vascular malformations. The company said the financing was led by Alta Partners.